CR20250057A - Composición farmacéutica de anticuerpo anti-cd20 y uso de la misma - Google Patents

Composición farmacéutica de anticuerpo anti-cd20 y uso de la misma

Info

Publication number
CR20250057A
CR20250057A CR20250057A CR20250057A CR20250057A CR 20250057 A CR20250057 A CR 20250057A CR 20250057 A CR20250057 A CR 20250057A CR 20250057 A CR20250057 A CR 20250057A CR 20250057 A CR20250057 A CR 20250057A
Authority
CR
Costa Rica
Prior art keywords
compositions
antibody
pharmaceutical composition
disorder
mediated disease
Prior art date
Application number
CR20250057A
Other languages
English (en)
Spanish (es)
Inventor
Aleksandra Aleksandrovna Sozonova
Dmitry Valentinovich Morozov
Ekaterina Aleksandrovna Lomkova
Aleksandr Olegovich Iakovlev
Arina Valerevna Zinkina-Orikhan
Daria Dmitrievna Bolsun
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2022127768A external-priority patent/RU2824627C2/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of CR20250057A publication Critical patent/CR20250057A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR20250057A 2022-07-26 2023-07-17 Composición farmacéutica de anticuerpo anti-cd20 y uso de la misma CR20250057A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2022120466 2022-07-26
RU2022127768A RU2824627C2 (ru) 2022-10-26 Фармацевтическая композиция анти-cd20 антитела и ее применение
PCT/RU2023/050174 WO2024025440A1 (fr) 2022-07-26 2023-07-17 Composition pharmaceutique d'anticorps anti-cd20 et son utilisation

Publications (1)

Publication Number Publication Date
CR20250057A true CR20250057A (es) 2025-08-13

Family

ID=89707083

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250057A CR20250057A (es) 2022-07-26 2023-07-17 Composición farmacéutica de anticuerpo anti-cd20 y uso de la misma

Country Status (14)

Country Link
CN (1) CN119997972A (fr)
AR (1) AR130008A1 (fr)
CL (1) CL2025000215A1 (fr)
CR (1) CR20250057A (fr)
DO (1) DOP2025000008A (fr)
JO (1) JOP20250015A1 (fr)
MA (1) MA70850A1 (fr)
MX (1) MX2025000682A (fr)
PE (1) PE20251691A1 (fr)
PY (1) PY2357704A (fr)
TW (1) TW202417044A (fr)
UY (1) UY40364A (fr)
WO (1) WO2024025440A1 (fr)
ZA (1) ZA202500495B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025247408A1 (fr) * 2024-05-31 2025-12-04 百奥泰生物制药股份有限公司 Utilisation d'un anticorps anti-cd20 ou d'un fragment de liaison à l'antigène de celui-ci dans le traitement de maladies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
RU2572800C1 (ru) * 2014-09-22 2016-01-20 Закрытое Акционерное Общество "Биокад" Новый состав, содержащий конъюгат пэг и интерферон-альфа-2бета, обладающий сниженной болезненностью при введении
HUE053366T2 (hu) * 2015-11-03 2021-06-28 Janssen Biotech Inc Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk
RU2724469C2 (ru) * 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с cd20
WO2021068971A1 (fr) * 2019-10-12 2021-04-15 Bio-Thera Solutions, Ltd. Formulation d'anticorps anti-cd20 et utilisation d'anticorps anti-cd20 pour le traitement de maladies positives pour le cd20

Also Published As

Publication number Publication date
TW202417044A (zh) 2024-05-01
CL2025000215A1 (es) 2025-06-13
AR130008A1 (es) 2024-10-23
PE20251691A1 (es) 2025-07-02
UY40364A (es) 2024-02-15
JOP20250015A1 (ar) 2025-01-23
WO2024025440A1 (fr) 2024-02-01
PY2357704A (es) 2024-05-16
MA70850A1 (fr) 2025-10-31
DOP2025000008A (es) 2025-02-28
ZA202500495B (en) 2025-08-27
MX2025000682A (es) 2025-03-07
CN119997972A (zh) 2025-05-13

Similar Documents

Publication Publication Date Title
MX390954B (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
CR20190403A (es) Una composición farmacéutica que comprende un anticuerpo anti-c5 contra una enfermedad relacionada con c5 y un producto de la misma
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
BR112018000212A2 (pt) uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer
CL2024002767A1 (es) Moduladores de nlrp3
MX2021000516A (es) Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5.
UY40003A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
CO2022014499A2 (es) Moduladores de nlrp3
DOP2025000008A (es) Composición farmacéutica de anticuerpo anti-cd20 y uso de la misma
CL2024003729A1 (es) Terapia combinada de agente activo anti-pd-1, agente activo anti-tim-3 y agente activo anti-lag-3 para tratar cáncer.
CL2024000669A1 (es) Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos
CO2023017186A2 (es) Formas cristalinas de trofinetida
ECSP23076276A (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
CO2022014853A2 (es) Compuesto novedoso [2-(dimetilamino)-2-fenilbutil]-3,4,5-trimetoxibenzoato 4-metil-2h-cromen-2-on-7-il sulfato y uso del mismo
MX2022011651A (es) Composicion farmaceutica para tratamiento de diabetes.
CL2023003209A1 (es) Composición farmacéutica de pembrolizumab y su uso
CO2023014650A2 (es) Dosificación y administración de l-asparaginasa recombinante
ECSP22092205A (es) Composición farmacéutica acuosa de levilimab y su uso
BR112022021105A2 (pt) Regime de dosagem para tratar uma doença modulada por csf-1r
PL436660A1 (pl) Kompozycja farmaceutyczna stosowana w leczeniu nowotworów
MX2022001083A (es) Micelas lipídicas anfifílicas peptídicas (palm) para tratamiento de neuropatía periférica inducida por quimioterapia relacionada con el tratamiento del cáncer.
BR112022010488A2 (pt) Formulação farmacêutica, uso da formulação farmacêutica, e, método para tratamento de um paciente
MX2025013233A (es) Formas polimorficas y formulaciones de leriglitazona
MX2024009564A (es) Composicion farmaceutica para tratamiento de cancer que comprende proteina de fusion que incluye il-12 y anticuerpo anti-fap, y uso de la misma.
MX2026001145A (es) Cocristal de un inhibidor de idh1, proceso de preparacion del mismo, composiciones farmaceuticas del mismo, y metodos de tratamiento que implican el mismo